Zobrazeno 1 - 10
of 12
pro vyhledávání: '"John B. Kurek"'
Autor:
Edward Byrne, John B. Kurek, Lawrence Austin, Timothy M. Bennett, Sandra J Feeney, M. J. Bernadette Jean-François, CM Muldoon
Publikováno v:
Cytokine. 23:108-118
Before potential therapeutic strategies for the treatment of amyotrophic lateral sclerosis (ALS) can be advanced to human clinical trials, there is a need to assess them in an animal model that best resembles the disease process. SOD1 G93A mice have
Publikováno v:
Brain Research. 922:144-147
Leukemia inhibitory factor (LIF) is a survival factor for motoneurons. In this study we investigated whether intense systemic LIF therapy prevents the loss of lumbar motoneurons in the transgenic SOD1 G93A mouse model of familial amyotrophic lateral
Publikováno v:
Muscle & Nerve. 19:1291-1301
The process of skeletal muscle regeneration following injury or disease involves locally produced growth factors which control cellular proliferation and differentiation. Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) have previously been
Publikováno v:
Neuromuscular Disorders. 6:105-114
Leukaemia inhibitory factor (LIF) and Interleukin-6 (IL-6) are multifunctional cytokines that are related on the basis of their predicted structural similarities and shared signal transducing receptor components. Both these factors stimulate myoblast
Autor:
Scott D. Freer, Wei Bu, Philip L. Stetson, Daniel W. Sved, John B. Kurek, Robert A. Boyd, Shelly Hollar
Publikováno v:
Rapid communications in mass spectrometry : RCM. 17(21)
A liquid chromatography/mass spectrometry (LC/MS) analytical procedure, using a single column for sample clean-up, enrichment and separation, has been developed for the determination of the peptide AM336 in monkey cerebrospinal fluid (CSF). CSF sampl
Publikováno v:
Cancer chemotherapy and pharmacology. 48(6)
Purpose: Peripheral neuropathy caused by the anticancer agents cisplatin and paclitaxel is a significant dose-limiting toxicity of these drugs. The growth factor leukaemia inhibitory factor (LIF) has neuroprotectant activity in preclinical models of
Publikováno v:
Musclenerve. 24(5)
Cell-based therapies, such as myoblast transfer therapy, are likely to become an integral part of any approach to treat myopathies such as Duchenne muscular dystrophy. Previous studies have shown that an increased level of regeneration in the host mu
Autor:
John B. Kurek, Sandra J Feeney, John J. Bower, Lawrence Austin, David E Crump, Anthony J Radford, Edward Byrne
Publikováno v:
Journal of the neurological sciences. 160
Growth factors are theoretically promising agents for ALS therapy, but have been disappointing in subcutaneous delivery due to either toxicity or lack of major efficacy. Leukaemia inhibitory factor (LIF), was named after its effect on haemopoietic ce
Publikováno v:
Neuroscience letters. 249(1)
A model of spinal trauma was developed where spinal neurones of adult mice were exposed to the excitotoxic glutamate analogue β - N -oxylamino- l -alanine ( l -BOAA). After 24 h, the injured neurones received a single dose of [ 125 I]-LIF at the sam
Autor:
John B. Kurek, John J. Bower, Mark Murphy, Margarita Romanella, Frank Koentgen, Lawrence Austin
Publikováno v:
Musclenerve. 20(7)
Although a number of cytokines have been implicated in tissue regeneration, it is unknown which ones actually function in vivo. Here, we use mice with a targeted mutation in the leukemia inhibitory factor (LIF) gene to examine the role of LIF in musc